These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34975586)

  • 1. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.
    Edinoff AN; Akuly HA; Wagner JH; Boudreaux MA; Kaplan LA; Yusuf S; Neuchat EE; Cornett EM; Boyer AG; Kaye AM; Kaye AD
    Front Psychiatry; 2021; 12():789982. PubMed ID: 34975586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.
    Yu C; Garcia-Olivares J; Candler S; Schwabe S; Maletic V
    J Exp Pharmacol; 2020; 12():285-300. PubMed ID: 32943948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Paediatr Drugs; 2021 Nov; 23(6):583-589. PubMed ID: 34523063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
    Nasser A; Hull JT; Liranso T; Busse GD; Melyan Z; Childress AC; A Lopez F; Rubin J
    Neuropsychiatr Dis Treat; 2021; 17():1751-1762. PubMed ID: 34113106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
    Childress A; Burton S
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
    Raible H; D'Souza MS
    Ann Pharmacother; 2023 Dec; 57(12):1436-1448. PubMed ID: 37021356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update.
    Haddad HW; Hankey PB; Ko J; Eswani Z; Bhatti P; Edinoff AN; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):37018. PubMed ID: 35910243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Maletic V; Mattingly GW; Earnest J
    Expert Rev Neurother; 2024 May; 24(5):443-455. PubMed ID: 38502148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2021 Feb; 296():113664. PubMed ID: 33418457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
    Faraone SV; Gomeni R; Hull JT; Chaturvedi SA; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2022 Dec; 318():114922. PubMed ID: 36375329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.
    Robinson CL; Parker K; Kataria S; Downs E; Supra R; Kaye AD; Viswanath O; Urits I
    Health Psychol Res; 2022; 10(3):38360. PubMed ID: 36168642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder.
    Mather K; Condren M
    J Pediatr Pharmacol Ther; 2022; 27(5):409-414. PubMed ID: 35845566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viloxazine: Pediatric First Approval.
    Lamb YN
    Paediatr Drugs; 2021 Jul; 23(4):403-409. PubMed ID: 34036533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult attention deficit hyperactivity disorder: a comprehensive review.
    Williams OC; Prasad S; McCrary A; Jordan E; Sachdeva V; Deva S; Kumar H; Mehta J; Neupane P; Gupta A
    Ann Med Surg (Lond); 2023 May; 85(5):1802-1810. PubMed ID: 37228994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
    Johnson JK; Liranso T; Saylor K; Tulloch G; Adewole T; Schwabe S; Nasser A; Findling RL; Newcorn JH
    J Atten Disord; 2020 Jan; 24(2):348-358. PubMed ID: 30924702
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.
    Nasser A; Gomeni R; Wang Z; Hull JT; Busse GD; Melyan Z; Fava M; O'Neal W; Rubin J
    Br J Clin Pharmacol; 2022 Nov; 88(11):4828-4838. PubMed ID: 35588245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Garcia-Olivares J; Yegla B; Bymaster FP; Earnest J; Koch J; Yu C; Rubin J
    J Exp Pharmacol; 2024; 16():13-24. PubMed ID: 38249320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.